Drug
Masitinib (4.5)
Masitinib (4.5) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
3
75%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Recruiting1
Completed1
Suspended1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 33 (75.0%)
Trials by Status
recruiting125%
completed125%
suspended125%
not_yet_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
suspendedphase_3
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
NCT05441488
not_yet_recruitingphase_3
Masitinib in Patients With Mild Alzheimer's Disease
NCT05564169
recruitingphase_3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
completedphase_2
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
NCT02588677
Clinical Trials (4)
Showing 4 of 4 trials
NCT05441488Phase 3
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
NCT05564169Phase 3
Masitinib in Patients With Mild Alzheimer's Disease
NCT03127267Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT02588677Phase 2
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4